Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults by Laws, S.M. et al.
1SCIENTIFIC REpoRtS | 7: 9766  | DOI:10.1038/s41598-017-09577-4
www.nature.com/scientificreports
Insulin resistance is associated with 
reductions in specific cognitive 
domains and increases in CSF tau in 
cognitively normal adults
Simon M. Laws  1,2,3, Scott Gaskin2, Amy Woodfield2, Velandai Srikanth4, David Bruce5, Paul 
E. Fraser6,7, Tenielle Porter1, Philip Newsholme2, Nadeeja Wijesekara6, Samantha Burnham8,9, 
Vincent Doré10,11, Qiao-Xin Li12, Paul Maruff12,13, Colin L. Masters12, Stephanie Rainey-Smith8, 
Christopher C. Rowe11,14, Olivier Salvado10, Victor L. Villemagne11,12,14, Ralph N. Martins8,15 & 
Giuseppe Verdile2,8
Growing evidence supports the hypothesis that type 2 diabetes (T2D) increases the risk of developing 
dementia. Experimental evidence from mouse models demonstrates that the induction of T2D/insulin 
resistance (IR) can promote the accumulation of Alzheimer’s disease (AD) pathological features. 
However, the association of T2D with pathological and clinical phenotypes in humans is unclear. Here 
we investigate the relationship of indices of IR (HOMA-IR) and pancreatic β-cell function (HOMA-B) with 
cognitive performance across several domains (Verbal/Visual Episodic Memory, Executive Function, 
Language and a measure of Global cognition) and AD biomarkers (CSF Aβ42, T-tau/P-tau, hippocampal 
volume and neocortical Aβ-amyloid burden). We reveal that HOMA-IR (p < 0.001) incrementally 
increases across diagnostic groups, becoming significantly elevated in the AD group compared with 
cognitively normal (CN) adults. In CN adults, higher HOMA-IR was associated with poorer performance 
on measures of verbal episodic memory (p = 0.010), executive function (p = 0.046) and global cognition 
(p = 0.007), as well as with higher CSF T-tau (p = 0.008) and P-tau (p = 0.014) levels. No association 
was observed with CSF Aβ or imaging modalities. Together our data suggest that IR may contribute 
to reduced cognitive performance and the accumulation of CSF tau biomarkers in cognitively normal 
adults.
Epidemiological studies indicate that Type 2 diabetes (T2D) is associated with an increased risk of dementia1–5. 
Clinical studies using cross-sectional designs support this association by showing that cognition is worse in 
patients with T2D as compared to matched controls without T2D6, 7. Furthermore, studies of structural magnetic 
resonance imaging (MRI) show that in T2D cognitive impairment is associated with greater levels of vascular 
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lesions as well as with brain atrophy6–10. Prospective MRI studies also show that in T2D brain atrophy occurs at 
faster rates than in normal ageing11, 12, suggesting that T2D accelerates neurodegeneration.
Animal studies provide additional evidence to show that inducing T2D/insulin resistance (IR) can promote 
the pathological changes characteristic of Alzheimer’s disease (AD), specifically accumulation of amyloid-beta 
(Aβ) and tau (see review ref. 13). These studies also implicate common inflammatory or oxidative stress pathways 
that link these two chronic diseases of ageing (see review ref. 14). However, the association between cognition and 
AD pathology in human studies and the stage of AD progression where IR has greater impact remains unclear. 
Evidence to date using Positron emission tomography (PET) studies have so far been inconclusive.
In AD, PET studies of cerebral glucose metabolism (18F-deoxyglucose PET: FDG-PET) and Aβ deposition 
(e.g. C11-Pittsburg compound B-PET: PiB-PET) show that reduced neuronal glucose metabolism and increased 
levels of neocortical Aβ accumulation are features that occur early in the disease (see review ref. 15). A small 
number of cohort studies have investigated the relationship between these imaging markers of AD and T2D. A 
cross-sectional study in the population-based Mayo Clinic Study of Ageing assessed cerebral glucose metabolism 
(FDG-PET) and Aβ deposition (PiB-PET) in healthy older and cognitively normal (CN) adults and older people 
with T2D. The study showed that compared to the controls, those with T2D displayed cerebral hypometabolism, 
particularly in those regions severely affected in AD, but no differences in neocortical amyloid load16. In the 
Baltimore, longitudinal study of Ageing (BLSA), no association was observed between measures of peripheral 
IR or glucose tolerance and neocortical Aβ load (in a PiB-PET scanned cohort) or other pathological features 
of AD in post-mortem brain17. More recently in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, 
no association was shown betweenT2D and accumulation of neocortical Aβ load (PiB-PET) or increases in CSF 
Aβ4210. Instead, T2D was associated with lower cortical thickness an increase in CSF total tau (T-Tau) and phos-
phorylated tau (P-tau). Together, these findings suggest that IR/T2D is not associated with cerebral accumulation 
of Aβ but with other hallmarks of the disease. However, in a recent cross-sectional study, Aβ deposition was 
associated with a higher Homeostatic Model Assessment of IR (HOMA-IR) in late-middle aged, normoglycaemic 
cognitively normal participants18. The conflicting results in the current literature may be in part due to demo-
graphic differences in populations (e.g. age, clinical staging of disease and disease progression) and study design. 
Further, recent meta-analyses suggest that sex can also mediate T2D associations with dementias and associated 
co-morbidities, such as stroke19–21. Thus, the relationship between IR and clinical and pathological features of the 
early stages of AD, and sex specific effects, requires further study, particularly in normoglycaemic individuals and 
prior to the onset of cognitive impairment.
In addition to IR, β-cell hyperactivity and dysfunction and subsequent hyperinsulinemia also contribute to 
hyperglycaemia and T2D (see review ref. 22). Further, recent evidence indicates β-cell dysfunction in AD rodent 
models23, 24 and that Aβ and Tau have been shown to accumulate in human post-mortem pancreatic tissue in 
T2D25, possibly contributing to β-cell dysfunction. Despite this evidence, there is a lack of literature investigating 
pancreatic β-cell activity (HOMA-B) on cognition and AD related pathology.
The overall aim of this study was to investigate if assessments of IR (HOMA-IR) or pancreatic β-cell func-
tion (HOMA-B) are altered across diagnostic groups and ascertain their associations with pathological and 
clinical expressions of AD in the well characterised Australian Imaging Biomarker and Lifestyle (AIBL) study. 
We hypothesised that HOMA-IR and HOMA-B are altered across diagnostic groups and are associated with 
poorer cognitive performance and higher burdens of neuroimaging/CSF biomarker load in cognitively normal 
participants.
Results
Clinical and cognitive descriptive data for the diagnostic groups [cognitively normal adults (CN), mild cognitive 
impairment (MCI) and AD] are presented in Tables 1 and 2, respectively. A significant difference in age and 
frequency of the Apolipoprotein E (APOE) ε4 allele was observed across all diagnostic groups (Table 1), with 
AD and MCI being older and having a significantly higher APOE ε4 frequency compared to CN (p < 0.001). 
Significant differences between groups for pathological features and cognitive measures confirmed a clear differ-
entiation between diagnostic groups (Table 2).
Relationships between T2D markers and clinical diagnosis. Serum glucose levels were increased 
significantly in AD and MCI compared with CN (p = 0.014) (AD > MCI > CN), and a non-significant trend 
was observed for serum insulin HOMA-IR, but not for HOMA-B (Table 1). These group differences in the 
HOMA indices became statistically significant after co-varying for BMI, sex, diabetes, use of diabetes medi-
cation, smoking, age and APOE genotype. HOMA-IR (Fig. 1A) was significantly increased across diagnostic 
groups (ANCOVA, F = 8.656, p < 0.001) with post-hoc analysis showing a significant increase in HOMA-IR 
in the AD group (Bonferroni p < 0.001) compared to CN. A clinical group difference was also observed for 
HOMA-B (Fig. 1B; F = 4.564, p = 0.011), though between the MCI and CN groups (Bonferroni p = 0.028). In 
both cases, significant differences were only observed in females (HOMA-IR, F = 6.989 p = 0.001; HOMA-B, 
F = 5.575 p = 0.004) but not males (HOMA-IR, F = 2.603 p = 0.075; HOMA-B, F = 0.911 p = 0.403). In females 
HOMA-IR was still only observed to be different in the AD group (Bonferroni p = 0.001) compared to CN, whilst 
HOMA-B, was significantly lower in CN compared to both the MCI (Bonferroni p = 0.041) and AD (Bonferroni 
p = 0.017) groups.
HOMA-IR is associated with cognitive performance and CSF biomarkers. A significant inverse 
relationships were observed (Table 3) between HOMA-IR and the cognitive composites, verbal episodic memory 
(β = −0.65, p = 0.010), executive functioning (β = −0.48, p = 0.046) and global composite (β = −0.68, p = 0.007). 
Significant positive relationships were also observed with CSF T-tau (β = 830.2, p = 0.008) and P-tau (β = 95.9, 
p = 0.014). Increases in HOMA-B were only observed to be associated with reductions in executive functioning 
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(β = −0.095, p = 0.044) and the global composite (β = −0.011, p = 0.043). Stratification by sex (Table 4, female; 
Table 5, male) revealed that prior significant associations held between HOMA-IR and verbal episodic mem-
ory (β = −0.63, p = 0.046), executive function (β = −0.61, p = 0.042), the global cognitive composite (β = −0.79, 
p = 0.014) and both CSF T-tau (β = 639.5, p = 0.048) and P-Tau (β = 93.4, p = 0.031) in females. No significant 
associations were observed for either HOMA-IR or HOMA-B in males.
Discussion
Our findings demonstrate modest yet significant differences, in both HOMA-IR and HOMA-B, between the 
clinical classifications of AD, MCI and CN within the AIBL cohort, after covarying for potential confounding 
variables. Within clinical classifications, compared to the CN group, the AD group had higher HOMA-IR. These 
findings are consistent with previous reports showing that the prevalence of IR is greater in MCI/AD patients 
than controls26–28. However, in the current study HOMA-B was increased only in the MCI group, suggesting an 
increase in β-cell function/insulin secretion in this group, an observation consistent with the observed trend 
towards increasing absolute insulin levels across groups. This may represent a response to control increasing 
glucose levels during disease progression29, which was also observed in this study. Overall, these initial find-
ings suggested that increased β -cell function/insulin secretion is associated with cognitive impairment, at least 
in non-demented adults. However, in the absence of overt cognitive impairment (i.e. CN group), compared to 
HOMA-IR, HOMA-B had no or weak associations with functioning of cognitive domains. This suggests that 
CN MCI AD P value
n 905 156 203
Age (years) 70.6 ± 6.8 75.1 ± 7.6 76.4 ± 7.7 <0.001
Sex (Female, %) 59.7 53.2 56.9 0.282
APOE ε4 (Positive, %) 26.8 53.2 63.7 <0.001
BMI 26.6 ± 4.1 25.5 ± 4.1 25.1 ± 4.4 <0.001
Diabetes (%) 7.8 7.7 9.3 0.772
Diabetic Medication (%) 4.9 6.4 6.9 0.431
Hypertension (%) 34.1 36.8 26.5 0.067
Smoking (%) 4.0 1.9 1.0 0.056
Insulin (mU/L) (Reference Range < 12) 7.42 ± 7.16 8.88 ± 12.2 8.12 ± 7.0 0.074
Glucose (mmol/L) (Reference range 3.0–5.4) 5.19 ± 0.79 5.20 ± 0.99 5.39 ± 1.30 0.014
HOMA-IR† 0.617 ± 0.189 0.635 ± 0.198 0.647 ± 0.191 0.091
HOMA-B† 4.73 ± 0.80 4.83 ± 0.90 4.76 ± 0.922 0.302
Table 1. Baseline demographic and clinical pathology data for clinical classifications across the cohort. All 
data is presented as means ± standard deviations or %, where indicated. CN, cognitive normal; MCI, Mild 
cognitively impaired; AD, Alzheimer’s disease; †HOMA indices underwent Box-Cox transformations prior to 
analysis.
CN MCI AD P value
Cognitive Composites
VEM 0.032 ± 1.20 (n = 891) −2.69 ± 1.49 (n = 146) −3.93 ± 1.70 (n = 152) <0.001
ViEM −0.010 ± 1.31 (n = 900) −2.02 ± 1.39 (n = 152) −4.42 ± 1.36 (n = 166) <0.001
EF 0.006 ± 1.08 (n = 883) −1.24 ± 1.23 (n = 146) −3.37 ± 1.89 (n = 139) <0.001
LANG 0.015 ± 0.72 (n = 887) −1.26 ± 0.90 (n = 153) −3.50 ± 1.32 (n = 174) <0.001
GLOBAL 0.026 ± 1.17 (n = 889) −3.07 ± 1.68 (n = 146) −6.37 ± 2.14 (n = 151) <0.001
Neuroimaging/CSF Biomarkers
HV (cm3) 2.93 ± 0.27 (n = 229) 2.62 ± 0.42 (n = 52) 2.39 ± 0.38 (n = 38) <0.001
NAB (SUVR-BeCKeT) 1.38 ± 0.40 (n = 262) 1.86 ± 0.53 (n = 69) 2.11 ± 0.50 (n = 48) <0.001
CSF Aβ42 681.2 ± 201.9 (n = 36) 590.3 ± 229.7 (n = 14) 496.9 ± 243.5 (n = 16) 0.022
CSF T-tau 330.6 ± 236.8 (n = 36) 512.0 ± 321.0 (n = 14) 587.5 ± 235.4 (n = 16) 0.003
CSF P-tau 58.2 ± 29.1 (n = 36) 75.4 ± 34.9 (n = 14) 79.6 ± 23.7 (n = 16) 0.031
CSF Aβ42:T-tau 2.72 ± 1.40 (n = 36) 1.77 ± 1.30 (n = 14) 1.01 ± 0.79 (n = 16) <0.001
CSF Aβ42:P-tau 13.82 ± 6.12 (n = 36) 10.35 ± 7.04 (n = 14) 6.85 ± 4.46 (n = 16) 0.001
Table 2. Baseline AD-related phenotypic data and cognitive descriptive statistics for clinical classifications 
across the cohort. All data is presented as means ± standard deviations. CN, cognitive normal; MCI, Mild 
cognitively impaired; AD, Alzheimer’s disease; VEM, Verbal Episodic Memory; ViEM, Visual Episodic 
Memory; EF, Executive Function; LANG, Language; GLOBAL, Global cognitive composite; HV, Intracranial 
volume corrected Hippocampal Volume; NAB, Neocortical Amyloid Burden; SUVR-BeCKeT, a transformation 
of native SUVR into PiB-like SUVR.
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changes in insulin sensitivity is the stronger, earlier contributor to impairments in cognition. Longitudinal anal-
ysis in the cognitively normal that do or do not show clinical disease progression may provide further support 
for this notion.
We also observed sex differences in levels of HOMA-IR and HOMA-B between diagnostic groups, where 
upon stratification by sex, the increases observed in the MCI or AD groups were only observed in females. These 
findings are consistent with outcomes from meta-analyses which indicate women with T2D are at higher risk of 
stroke and dementia compared to men with T2D19–21 and may be a consequence of several factors. For exam-
ple, studies in different ethnic groups have suggested that age related increases in the prevalence of metabolic 
syndrome are greater in women then in men (see review ref. 30). Similarly, impaired glucose tolerance has been 
reported to be more prevalent in older women than men, although impaired fasting glycaemia more prevalent 
in men31. Further, changes in hormonal status also contribute to an age-associated increased prevalence of met-
abolic syndrome in women32 and may be driven by androgen/oestrogen imbalances during the peri-menopausal 
period33. For example reduction in the neuroprotective effects of oestrogen or increases in gonadotropins may 
act to promote AD related pathological changes (see review ref. 34). With longitudinal study, the interactions 
between biological markers of IR and indices of AD related biology, and its clinical expression, would provide 
evidence to confirm our findings that these differences are stronger in woman than men, whilst also providing an 
indication of the potential contributions of hormones.
Having shown that increases in IR were associated with clinical stages of AD, we wished to ascertain the asso-
ciations of HOMA-IR and HOMA-B with pathological and clinical expressions of AD prior to the onset of clinical 
cognitive impairment. In the CN group, greater HOMA-IR was associated with reductions in global cognition 
and in two of the four cognitive domains assessed, namely verbal episodic memory and executive functioning. A 
weaker association was observed between HOMA-B and executive function and global cognition. Our findings 
are in agreement with previous studies showing similar associations of cognitive functioning with HOMA-IR in 
cognitively normal individuals from community-based volunteer35, population based36 or family based37 studies. 
Episodic memory is one of the earliest cognitive domains that show changes in the pre-clinical stages of AD. 
Previous studies have observed episodic memory changes occurring 4–8 years prior to executive function and 
up to 10-years prior to changes in other cognitive domains38–40. Compared to non-diabetics, verbal memory and 
executive functioning are also strongly affected in T2D41, 42. The association of IR with episodic memory suggests 
that it plays a role at early preclinical stages of the disease process.
Figure 1. HOMA-IR (A) and HOMA-B (B) at baseline within the clinical classifications of AIBL: *HOMA-IR 
and HOMA-B represented as Estimated Marginal Means ( ± SEM) of Box-Cox transformed raw data. 
Univariate analysis was performed covarying for BMI, sex, %diabetes, %diabetes medication, %hypertension, 
smoking, age and APOE ε4 (HOMA-IR, F = 8.656, p < 0.001; HOMA-B, F = 4.564, p = 0.011). Presented 
p-values are calculated using Post-hoc Bonferoni analysis.
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Stratification by sex revealed these associations were again present in females only. In previous studies, there 
have been varied findings with respect to the effect of sex on the association between HOMA-IR and cognitive 
functioning. In a cross-sectional study of cognitively healthy elderly community volunteers, higher HOMA-IR 
Cognitive Composites
VEM ViEM EF LANG Global
β Sig β Sig β Sig β Sig β Sig
HOMA-IR −0.65 0.010 −0.18 0.527 −0.467 0.046 −0.21 0.180 −0.68 0.007
HOMA-B −0.09 0.093 −0.04 0.451 −0.10 0.044 −0.02 0.459 −0.11 0.043
Neuroimaging/CSF Biomarkers
NAB HV CSF T-tau CSF P-tau CSF Aβ42 CSF Aβ42:T-tau CSF Aβ42:P-tau
β Sig β Sig β Sig β Sig β Sig β Sig β Sig
HOMA-IR 0.06 0.691 −0.05 0.542 830.2 0.008 95.9 0.014 −99.2 0.712 −3.30 0.066 −11.9 0.128
HOMA-B −0.02 0.490 0.01 0.538 125.3 0.08 155.7 0.08 9.63 0.871 −0.52 0.193 −2.05 0.243
Table 3. Relationship between HOMA indices and cognitive composites and neuroimaging/CSF biomarkers 
in cognitively normal older adults. Linear regression analysis covarying for (in all dependent variables) APOE 
ε4, BMI, %Diabetes, %Diabetes medication, %Hypertension and smoker and (for biomarkers only) sex and age. 
VEM, Verbal Episodic Memory; ViEM, Visual Episodic Memory; EF, Executive Function; LANG, Language; 
GLOBAL, Global cognitive composite. HV, Intracranial volume corrected Hippocampal Volume; NAB, 
Neocortical Amyloid Burden; CSF, Cerebrospinal Fluid.
Cognitive Composites
VEM ViEM EF LANG Global
β Sig β Sig β Sig β Sig β Sig
HOMA-IR −0.63 0.046 −0.45 0.220 −0.61 0.042 −0.25 0.218 −0.79 0.014
HOMA-B −0.08 0.222 −0.07 0.367 −0.10 0.134 −0.01 0.800 −0.11 0.111
Neuroimaging/CSF Biomarkers
NAB HV CSF T-tau CSF P-tau CSF Aβ42 CSF Aβ42:T-tau CSF Aβ42:P-tau
β Sig β Sig* β Sig β Sig β Sig β Sig β Sig
HOMA-IR 0.09 0.570 −0. 16 0.155 687.0 0.023 93.4 0.031 −107.8 0.804 −4.64 0.094 −17.4 0.131
HOMA-B 0.01 0.666 −0.02 0.480 136.4 0.056 19.4 0.055 50.2 0.613 −0.65 0.325 −2.44 0.369
Table 4. Relationship between HOMA indices and cognitive composites and neuroimaging/CSF biomarkers 
in cognitively normal older adults (FEMALES). Linear regression analysis covarying for (in all dependent 
variables) APOE ε4, BMI, %Diabetes, %Diabetes medication, %Hypertension and smoker and (for biomarkers 
only) age. VEM, Verbal Episodic Memory; ViEM, Visual Episodic Memory; EF, Executive Function; LANG, 
Language; GLOBAL, Global cognitive composite. HV, Intracranial volume corrected Hippocampal Volume; 
NAB, Neocortical Amyloid Burden; CSF, Cerebrospinal Fluid.
Cognitive Composites
VEM ViEM EF LANG Global
β Sig β Sig β Sig β Sig β Sig
HOMA-IR −0.63 0.133 0.15 0.731 −0.28 0.452 −0.13 0.601 −0.48 0.252
HOMA-B −0.16 0.057 0.05 0.579 −0.09 0.223 −0.06 0.241 −0.16 0.060
Neuroimaging/CSF Biomarkers
NAB HV CSF T-tau CSF P-tau CSF Aβ42 CSF Aβ42:T-tau CSF Aβ42:P-tau
β Sig β Sig β Sig β Sig β Sig β Sig β Sig
HOMA-IR 0.00 0.999 0.15 0.227 857.8 0.280 82.0 0.387 −333.0 0.369 −2.53 0.387 −10.45 0.413
HOMA-B −0.07 0.191 0.04 0.06 134.7 0.448 13.64 0.515 −79.0 0.328 −0.41 0.530 −1.97 0.540
Table 5. Relationship between HOMA indices and cognitive composites and neuroimaging/CSF biomarkers in 
cognitively normal older adults (MALES). Linear regression analysis covarying for (in all dependent variables) 
APOE ε4, BMI, %Diabetes, %Diabetes medication, %Hypertension and smoker and (for biomarkers only) age. 
VEM, Verbal Episodic Memory; ViEM, Visual Episodic Memory; EF, Executive Function; LANG, Language; 
GLOBAL, Global cognitive composite. HV, Intracranial volume corrected Hippocampal Volume; NAB, 
Neocortical Amyloid Burden; CSF, Cerebrospinal Fluid.
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was associated with lower verbal fluency performance and reduced grey matter in the temporal lobe of both men 
and women35. However, in a large, family based Dutch study of 1898 participants, higher HOMA-IR was asso-
ciated with poorer executive functioning in women only37. A similar association with verbal fluency in women 
only was shown recently in a population based study of ~6000 adults36. This association was independent of a 
marker of glucose levels (glycated haemoglobin; HbA1c), indicating that IR may have early effects on cognition 
and maybe detected prior to development of significant hyperglycaemia and T2D36. Further, in the same study 
HOMA-IR was associated with poorer verbal fluency in APOE ε4 non-carriers only. Several factors could account 
for these mixed results including age, cohort characteristics (family vs population vs community based) and the 
size of the cohort. For example, those studies that show associations in women only36, 37 the analysis was under-
taken in larger family or population based cohorts or were younger (~45 yrs. and 53 yrs., respectively) compared 
to our study and that of Benedict and colleagues35 (71 and 73 yrs., respectively).
IR was also associated with biomarkers of AD pathology within the cognitively normal group where increases 
in HOMA-IR were associated with increases in CSF T-tau and P-tau. No such relationships were observed with 
neocortical Aβ burden or CSF-Aβ42 in these groups. These findings suggest that, at earlier stages of the disease 
process there is a stronger relationship with tau rather than Aβ. Cross-sectional cohort studies evaluating imaging 
modalities (structural MRI, PET) or AD biomarkers have shown similar results. In these studies, lower cortical 
thickness and cerebral hypometabolism, but not changes in Aβ were associated with T2D8, 16, 17. More recently, in 
the ADNI study, T2D-related reduction in cortical thickness was associated with increases in CSF P-tau, but not 
with neocortical Aβ burden or CSF Aβ42, across diagnostic groups of CN, MCI, and AD10. Our study was not 
powered to similarly stratify for T2D as only a small proportion (~8%) of the total cohort had the condition. The 
association of HOMA-IR with increases in CSF tau, even after controlling for T2D, suggests that IR is an early 
contributor to this process. However, it is acknowledged that this is a cross-sectional analysis and a longitudinal 
follow-up is required to further establish IR as a determinant of cognitive decline and accumulation of AD patho-
logical features.
Numerous studies in various animal models have shown that diet (HF diet/sucrose/fructose) or chemical 
(administration of the β-cell toxin streptozotocin (STZ)) induced diabetes promote, tau phosphorylation, and 
synaptic/neurodegeneration23, 43–47. The potential mechanisms may involve neuroinflammatory and oxidative 
stress mechanisms14. In addition, impaired cerebral insulin signalling, promoted by IR and T2D, plays a key role 
in this process and in triggering tau hyper phosphorylation through increased activity of GSK-3β, a major protein 
kinase that phosphorylates tau (see review ref. 13). These in vivo, animal studies also support a role for T2D/IR 
in promoting Aβ build up in the brain, where availability of Aβ degrading enzymes such as the insulin degrading 
enzyme is reduced, inflammatory and oxidative processes promoting Aβ accumulation and formation of toxic 
oligomers further exacerbating synaptic degeneration (see review ref. 13). As discussed above the findings from 
the current study and others10, 16, 17 do not fully support this notion in human studies, but do not rule out the 
possibility that IR is associated with early deposition of Aβ.
Two recent studies have shown increases in HOMA-IR associated with increases in Aβ18, 48. The study by 
Willette et al.18, showed that higher HOMA-IR was associated with higher amyloid load (as assessed by PiB-PET) 
in normoglycaemic participants recruited from the Wisconsin Registry for Alzheimer’s disease Prevention 
(WRAP). The study performed analysis of HOMA-IR with PiB-PET and did not include CSF Aβ42, or CSF 
T-tau/P-tau levels. The more recent study by Hoscheidt et al.48 assessed participants with a parental history 
of dementia due to AD recruited from a similar cohort, the Wisconsin Alzheimer’s Disease Research Centre 
(ADRC), Investigating memory in people at risk, causes and treatments (IMPACT). The study investigated the 
association of HOMA-IR with CSF AD related biomarkers including Aβ42, CSF sAPPα/sAPPβ and CSF P-tau 
and showed that increases in HOMA-IR was associated with increased CSF levels of sAPPβ (not sAPPα), and 
modest association with CSF Aβ42 only. These findings were consistent with IR promoting amyloidogenic pro-
cessing of APP (i.e. increased sAPPβ) and thus Aβ42 formation. Whilst associations between HOMA-IR and 
neocortical Aβ burden were not assessed in the latter study, the findings were suggestive of being consistent with 
that previously observed18.
There are number of factors that may account for the differences in the findings in our cohort and the 
Wisconsin cohorts. Age may have a major role in determining where in the progression of AD pathology, IR has 
the greatest impact. The participants in the Wisconsin studies were younger (57.7 yrs49, and 60 yrs18) compared to 
our study cohort (CN average age 70 yrs.) and other cohorts where no associations with Aβ-amyloid was reported 
(~75 yrs.10 and ~79 yrs.17). Therefore, it is possible that an earlier relationship occurs between IR and Aβ-amyloid 
burden, but in older and presymptomatic individuals a relationship with Tau exists. Longitudinal studies that 
incorporate Aβ-amyloid imaging, tau imaging and CSF Aβ/tau biomarkers are required to map out where IR fits 
into the progression of the disease. However, both relationships may be useful in the possible use of IR as a factor 
that contributes to predicting the conversion to cognitive impairment from pre-symptomatic stages.
It is also worth noting that the Wisconsin cohorts had a high percentage of participants with a family history 
of dementia due to AD, and in the Hoescheidt et al. study49, analysis was only performed on those with a family 
history. In addition, 47% of the cohort were APOE ε4 carriers compared to 26.8% in this study and CSF sAPPβ 
and P-tau/Aβ42 were higher in APOE ε4 carriers. The Willette et al.18 study also had a higher percentage of 
APOE ε4 carriers (38.7%). The carriage of APOE ε4 is associated with greater CSF Aβ42 and Aβ-amyloid plaque 
load50–53, a strong predictor of AD pathology and cognitive decline54, 55. The apoE4 isoform is also thought to have 
a greater impact on Aβ accumulation, through impairing clearance/degradation56–60, but also has been associated 
with the dysregulation of APP processing to promote Aβ production61, 62. These characteristics of the Wisconsin 
cohorts may also explain the greater association of HOMA-IR with Aβ-amyloid pathology compared to what we 
observe in the AIBL cohort.
Our findings, in CN adults, indicate that increases in IR are associated with reductions in cognition function 
and elevations in CSF tau. This and other studies suggest that IR may contribute to AD progression, although 
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it is possible that it is AD pathology that gives rise to metabolic dysfunction. For example, evidence from AD 
post-mortem studies shows brain regions involved in regulating brain and systemic energy metabolism, such as 
the hypothalamus contain Aβ plaques and Tau tangles (see review ref. 63). Further, FDG-PET studies show low-
ered hypothalamic glucose metabolism in MCI or AD than in age matched controls. Additionally, animal studies 
suggest that peripheral Aβ may drive IR and glucose dysregulation and that tau may be important in maintaining 
glucose homeostasis (see review ref. 64). Our findings that IR is associated with preclinical reductions in cognitive 
performance and increased CSF tau levels contribute to this understanding of the relationship between IR and 
AD. These data are also consistent with those from a recent cross-sectional study from the ADNI cohort which 
observed that T2D-related brain atrophy was associated with increases in CSF P-tau in CN, MCI and AD groups 
and which led to the conclusion that T2D may promote neurodegeneration independent of AD dementia diag-
nosis10. Our observed associations of increasing IR with reductions in cognition and increases in CSF T-tau and 
P-tau in CN adults suggests IR may also lead directly to changes in cognition and tau accumulation in early AD. 
Longitudinal analysis, particularly in controls/MCI participants that convert may provide some insight into the 
direction of this association. Ideally, these studies would be complemented with PET imaging of relevant brain 
regions including the hypothalamus. Although, FDG-PET studies have shown reduced glucose utilisation in the 
AD/MCI hypothalamus65, 66 studies with Aβ or tau tracers have not been forthcoming, potentially due to the small 
size of the hypothalamus, limiting spatial resolution, and off-target binding, which may increase the difficulty in 
assessing this brain region.
There are some limitations to our findings. Firstly, there is the potential that observed findings are currently 
sample dependent for several reasons; participants were volunteers and not randomly selected from the commu-
nity, therefore the findings of this study may only be applicable to similar cohorts and the study used cognitive 
composites derived from specific cognitive assessments, and the use of similar composites derived from different 
cognitive assessments may result in different findings. Second, the analysis is cross-sectional and informs that 
there is an association of HOMA indices with cognitive functioning. The findings merit longitudinal analysis to 
determine if; (1) insulin resistance is associated with the progression of AD pathology and at what stages this rela-
tionship is observed (i.e. amyloid at early stages/ tau at later stages) and (2) the contribution of IR/T2D to predict-
ing cognitive impairment. The HOMA indices are calculated from fasting glucose and insulin levels. Although 
commonly used in association studies, particularly large cohort studies, a closer measure of insulin sensitivity is 
utilising the euglycaemic-hyperinsulinaemic clamp to quantify insulin secretion and assess metabolism of glu-
cose. Given that this method requires to be done in a clinical setting it would not be feasible in large cohort stud-
ies, but once confirmation of a role for IR in the progression of the disease/conversion to cognitive impairment/
AD pathology, studies could be undertaken in a small subset to tease out potential mechanisms. As the focus was 
associations with IR, our study variables did not include cardiovascular or atherosclerotic factors (i.e. cholesterol, 
triglycerides), however recent studies investigating the relationship of IR with atherosclerotic factors in AD/MCI 
patients show that increased insulin/decreased response to insulin are independent predictors for AD and MCI67.
We have demonstrated that in the AIBL cohort increases in HOMA-IR are associated with reductions in 
cognitive domains that show early changes in AD with concomitant increases in CSF tau levels. Longitudinal 
analysis in this and additional cohorts that incorporate tau imaging would be requried to confirm this association 
with accumnulation of pathological changes. A similar analysis in individuals at risk will also determine if there 
are earlier associations with Aβ burden and if T2D contributes to the conversion of pre-sympotmatic to early 
cogntive impairment (MCI) or MCI to AD. As early IR, prior to significant hyperglycaemia, is modifiable this 
work has implications in identifying and assessing strategies to reduce/prevent the onset cognitive decline and 
pathology associated with T2D.
Materials and Methods
Participants. The study reports on data collected from the AIBL study, a prospective longitudinal study of 
ageing. This cross-sectional study presents baseline data from 1264 participants (905 cognitively normal (CN), 
156 mild cognitive impaired (MCI), 203 Alzheimer’s disease (AD)). Information regarding AIBL study design, 
enrolment process, neuropsychological assessments and diagnostic criteria has been previously described68. 
Ethics approval for the AIBL study and all experimental protocols was provided by the ethics committees of 
Austin Health, St Vincent’s Health, Hollywood Private Hospital and Edith Cowan University. All experiments 
and methods were carried out in accordance with the approved guidelines and regulations and all volunteers gave 
written informed consent before participating in the study.
Cognitive Measures. The neuropsychological test battery administered in the AIBL study has been 
described in detail previously68. This included the Mini-Mental State examination (MMSE), Clock drawing test, 
California Verbal Learning Test- Second edition (CVLT-II), Logical Memory I and II (LMI; LMI; Story A only), 
D-KEFS verbal fluency, a 30-item version of the Boston Naming Test (BNT), Wechsler Test of Adult Reading 
(WTAR), Digit Span and Digit Symbol-Coding subtests of the Wechsler Adult Intelligence Scale-Third edition 
(WAIS-III), the Stroop task (Victoria version), and the Rey Complex Figure Test (RCFT). Cognitive measures 
are presented as five domain specific composite scores, derived from data collected from the neuropsychological 
battery as previously published by69. The five domain composites included in this study were; Verbal Episodic 
Memory (VEM; CDR sum of boxes (CDRSB), LMII CVLT false positives (CVLTFP) and long delay free recall 
(CVLTLDFR)), Visual Episodic Memory (ViEM; CDRSB, RCFT; 3 and 30 minute delayed recall, and recognition 
hits (RCFT3DR, RCFT30DR and RCFTHits)), Executive Functioning (EF; CDRSB, Stroop, Verbal Fluency Task (FAS), 
Category Switching Total (CatSwTot)), Language (LANG; CDRSB, Category Fluency (CatFl), BNT) and a statisti-
cally driven global composite (CDRSB, MMSE, LMII, CVLTFP and Clock), the latter aimed as a sensitive measure 
for longitudinal decline in individuals predisposed to AD69. All composites were calculated with a correction 
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for age, sex, years of education, premorbid IQ (WAIS-III Full Scale Intelligence Quotient (FSIQ) and depressive 
symptoms (Geriatric Depression Scale (GDS))69.
Biochemistry, Genotyping and HOMA estimations. Baseline fasted blood samples were taken and 
fractionated, with one aliquot sent to clinical pathology laboratories in Perth and Melbourne, as described previ-
ously68. As part of the clinical pathology assessment, fasting plasma insulin (FPI) and fasting plasma glucose levels 
(FPG) were assessed. The stated reference ranges are the ranges established in the clinical pathology laboratory in 
accordance with the national guidelines (http://www.nata.asn.au/, http://www.health.gov.au/npaac). The FPI and 
FPG were used to calculate values of Homeostatic modelling assessment (HOMA). The HOMA model is often 
used in cross-sectional and longitudinal studies to estimate insulin sensitivity and pancreatic β-cell functioning 
as alternatives to more direct assessments such as glucose clamping or acute insulin response, which are not prac-
tical in large cohort studies (see review ref. 70). Initially, comparisons of two methods of HOMA was performed; 
the HOMA1 (“original method”) using equations developed by Mathews and colleagues71 and the HOMA2 “the 
computer model”) developed by Levy and colleagues72. These models and the differences between them have been 
extensively discussed elsewhere70. HOMA1 was calculated using the following: HOMA-IR = (FPI x FPG)/22.5; 
HOMA-B (%) = (20x FPI)/(FPG = 3.5) to estimate IR and β-cell functioning respectively. HOMA2 was calculated 
from a Microsoft Excel macro accessed via the Oxford University website (www.dtu.ox.ac.uk/homacalculator/). 
Pearson’s correlation analysis of the data generated from HOMA1 and HOMA2 analysis revealed a strong signifi-
cant correlation between these indices (HOMA1-IR vs HOMA2-IR, r = 0.976, p < 0.001; HOMA1-B vs HOMA2 
B, r = 0.717, p < 0.0001), indicating suitability of both methods for this data set. However, HOMA1 was utilised 
as it is the most commonly used method in large cohort cross-sectional or longitudinal studies. All reference to 
HOMA in this report reflects HOMA1 calculated indices.
DNA was extracted and APOE genotype determined previously described73. Briefly, QIAamp DNA Blood 
Maxi Kits (Qiagen, Hilden, Germany) were used per manufacturer’s instructions to extract from whole blood. 
APOE genotype was determined from two separate TaqMan® (Thermo Fisher Scientific, Waltham, MA) genotyp-
ing assays for the single nucleotide polymoprhisms rs7412 (assay ID: C____904973_10) and rs429358 (assay ID: 
C___3084793_20). TaqMan® genotyping assays were performed on a QuantStudio 12 K Flex™ Real-Time-PCR 
systems (Thermo Fisher Scientific, Waltham, MA) using the TaqMan® GTXpress™ Master Mix (Thermo Fisher 
Scientific, Waltham, MA) methodology as per manufacturer instructions. APOE carrier status was defined by the 
presence (1 or 2 copies; ε4 + ) or absence (0 copies; ε4−) of the APOE ε4 allele.
CSF collection and Aβ42, T-tau, and P-tau181P quantitation were performed as previously described74. Briefly, 
approximately 10–14 ml of CSF was collected in the morning by routine lumbar puncture after overnight fasting 
directly into one 15 ml polypropylene tube (Greiner Bio-One188271), employing a protocol like that recom-
mended by the Alzheimer’s Biomarkers Standardization Initiative75. All CSF samples for analysis were taken 
from aliquots prepared and stored as previously described74 and thawed at time of assay. All CSF samples were 
analyzed in duplicate using the enzyme-linked immunosorbent assay (ELISA): INNOTEST Aβ-amyloid (1–42; 
Aβ42), INNOTEST hTAU Ag (T-tau), and INNOTEST Phospho-tau (P-tau; 181 P; P-tau181P) (Innogenetics, 
Ghent, Belgium) per published standard methods. Mean intra-assay coefficients of variation for these assays are 
as previously published74. This study reports on data from 66 study participants from whom CSF was taken at the 
baseline time point of the AIBL study.
Brain Imaging. Data was available at baseline from a total of 379 AIBL participants (262 CN, 69 MCI, 48 
AD) who underwent Aβ-amyloid imaging with positron emission tomography using either 11C-Pittsburgh 
Compound B (PiB), 18F-florebetapir or 18F-Flutemetamol as described elsewhere76–78. PET standardized uptake 
value ratios (SUVR) were determined for all tracers using CapAIBL, a web based freely availably MR-less meth-
odology79. Briefly, SUVs were summed and normalized to either the cerebellar cortex SUV (PiB), whole cerebel-
lum SUV (florbetapir, FBP) or pons SUV (flutemetamol, FLUTE) to yield the target-region to reference-region 
SUVR. To allow for the analysis of tracer specific SUVRs as a single continuous variable, a linear regression 
transformation, termed the “Before the Centiloid Kernel Transformation” (BeCKeT) scale, was applied to FBP 
and FLUTE SUVR to generate PiB-like SUVR units80.
Hippocampal Volume data was available for 319 (229 CN, 52 MCI, 38 AD) participants at baseline. 
Hippocampal volumes were determined through MRI, parameters of which have been previously described81. 
Briefly, participants underwent T1 weighted MRI using the ADNI 3-dimensional (3D) Magnetization Prepared 
Rapid Gradient Echo (MPRAGE) sequence on 1.5 T or 3 T scanners. Hippocampal volume was calculated after 
correcting for age in years and intracranial volume (sum of grey matter, white matter and cerebrospinal fluid 
volumes), as previously described82.
Statistical analysis. All statistical analysis was conducted using IBM SPSS Statistics (version 23; IBM 
Corp, Armonk, NY, USA) with the level of significance set to α = 0.05 (two-tailed). All variables were assessed 
for conformation to a normal distribution. Box-Cox transformations was used to correct variables depart-
ing from a normal distribution83. For all variables, except HOMA indices, the calculated lambda (λ) equated 
to no transformation. HOMA indices underwent transformations (T(Y)) prior to analysis, specifically: 
T(Y) = ((Y + 1)−0.079−1)/−0.079 and T(Y) = (Y0.04−1)/0.04 for HOMA-IR and HOMA-B, respectively (with Y 
representing the HOMA index). Analysis of demographic variables was undertaken using a One-way Analysis of 
Variance (ANOVA) to determine differences in continuous variables across clinical classifications differences in 
categorical variables determined using the χ2-test. Differences in HOMA indices between clinical classifications 
were assessed using an analysis of covariance (ANCOVA) via a General Linear Model (GLM) with Bonferroni 
correction. Associations between HOMA indices and cognitive composites and pathological brain changes in CN 
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were assessed using linear regression analysis. Both ANCOVA and linear regression analyses, for all dependent 
variables, covaried for body mass index (BMI), diabetes (yes/no), diabetes medication (yes/no), hypertension 
(yes/no), smoking (yes/no), and APOE genotype (ε4+/ε4−), with sex and age only covaried for with biomarker 
dependent variables.
Data availability. All data and samples used in this study are derived from the Australian Imaging, 
Biomarkers and Lifestyle (AIBL) Study of Ageing. All AIBL data, and that specific to this study, is publically 
accessible to all interested parties through an Expression of Interest procedure and is governed by the AIBL Data 
Use Agreement, for more information please see https://aibl.csiro.au/awd/.
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